FIELD: medicine.
SUBSTANCE: invention relates to the use of ranibizumab in the treatment of chorioretinal neovascular or permeability disorders in children. Use of ranibizumab for treating a child includes administering ranibizumab in the indicated child’s eye at a dose of 0.2 mg for children aged 2–4 years and at a dose of 0.3 mg for children aged 5–11 years.
EFFECT: invention provides a safe and effective treatment for children with chorioretinal neovascular disorders or permeability disorders due to optimally selected doses of ranibizumab.
13 cl, 2 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF SIROLIMUS FOR TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH PERSISTENT EDEMA | 2017 |
|
RU2765728C2 |
| USE OF VEGF ANTAGONIST FOR TREATING RETINOPATHY OF PREMATURITY | 2014 |
|
RU2676303C2 |
| METHOD FOR TREATMENT OF EYE DISEASES | 2015 |
|
RU2771900C2 |
| METHOD OF TREATING EYE DISEASES | 2015 |
|
RU2722643C2 |
| LIPOSOME FORMULATIONS | 2013 |
|
RU2680096C2 |
| LIPOSOMAL PREPARATIONS | 2013 |
|
RU2817350C2 |
| OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITIONS FOR NEOANGIOGENIC EYE PATHOLOGIES | 2009 |
|
RU2519739C2 |
| METHODS FOR TREATMENT OF EYE DISEASES | 2019 |
|
RU2776850C2 |
| INTEGRIN RECEPTOR ANTAGONISTS AND USE THEREOF | 2012 |
|
RU2721907C2 |
| NUTRICEUTICAL OPHTHALMOLOGICAL COMPOSITION FOR TREATMENT OF RETINAL PATHOLOGIES WITH A NEOVASCULAR COMPONENT | 2019 |
|
RU2806096C2 |
